Novo Nordisk A/S
Novo Nordisk A/S is a Denmark-based healthcare company focused on medicines and delivery systems for diabetes, obesity care, and rare diseases. It develops, manufactures, and markets branded prescription therapies and associated devices across a global commercial footprint from its headquarters in Denmark.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenuePrescription medicines and related products used to treat diabetes, including GLP-1 and insulin therapies.
Anti-obesity prescription medicines and associated patient access solutions.
Specialty treatments for hemophilia and other rare endocrine disorders.
Injection systems, pens, and other supporting pharmaceutical products and services.
Customers
Novo Nordisk sells primarily to healthcare systems, payers, pharmacies, and distributors that place prescription medicines with patients through retail, hospital, and specialty channels. End users are patients with chronic metabolic and rare diseases, while access and reimbursement decisions are heavily influenced by public and private payers.
Buy diabetes and rare disease medicines through national reimbursement, tender, and formulary channels.
Buy or reimburse branded medicines based on access, rebates, and utilization management terms.
Dispense and distribute the company’s prescriptions to patients across retail and specialty channels.
Use selected rare disease and injectable therapies in clinical settings.
Ultimate users of diabetes and obesity medicines, often via reimbursement or self-pay pathways.
Strategy
Novo Nordisk’s strategy centers on expanding access to its core chronic-disease medicines, broadening patient reach, and supporting launches across its major therapeutic areas. The company is also investing in manufacturing and supply chain capacity so it can support higher volumes, protect supply reliability, and maintain access across diverse reimbursement systems.
Long-term growth depends on getting more patients onto chronic disease therapies through access and reimbursement channels.
Higher volumes in diabetes and obesity require more API, fill-finish, and packaging capacity.
Obesity care is a major growth engine and needs broad physician, payer, and patient adoption.
Diabetes remains the base business and supports scale, cash generation, and commercial relationships.
Geography
Novo Nordisk markets its products in around 170 countries and operates across major regions including the Americas, International Operations, and APAC. The filings highlight that sales performance varies by region, with the United States especially important because of its pricing, rebate, and access dynamics, while Europe, China, and other international markets shape volume growth and product mix.
Risks
Novo Nordisk faces pricing, reimbursement, and access pressure in the U.S. and other major markets because its products are sold through heavily managed healthcare systems. The company is also exposed to patent disputes, product competition, supply interruptions, and impairment risk in its pipeline and intangible assets, all of which can affect growth and reported earnings.
- U.S. pricing and rebate pressureImpact: HighLikelihood: High
Sales depend heavily on managed access channels where rebates, 340B, and payer terms affect realized prices.
Exposure: United States commercial and government channels
- Competitive pressure in GLP-1 and insulinImpact: HighLikelihood: High
Therapy classes with strong demand also attract intense competition and market-share shifts.
Exposure: Diabetes and obesity franchises
- Patent and exclusivity disputesImpact: HighLikelihood: Medium
Core molecules and formulations face legal challenges and potential loss of protection over time.
Exposure: Semaglutide and related products
- Manufacturing and supply disruptionsImpact: HighLikelihood: Medium
Biopharma supply depends on complex API, fill-finish, and packaging networks.
Exposure: Global production network
- Intangible asset impairmentImpact: MediumLikelihood: Medium
Pipeline projects can fail or underperform, forcing non-cash write-downs.
Exposure: R&D pipeline assets
Accounting
Judgemental itemsReversals of U.S. sales rebate provisions can materially boost reported revenue in a period without any cash effect.
Impact: Reported sales and comparability
Pipeline assets such as monlunabant can require non-cash write-downs when expected value changes.
Impact: Operating profit and asset base
Hedging gains and losses can swing financial items, especially versus the U.S. dollar.
Impact: Net financial items and earnings
Large API, fill-finish, and packaging investments affect depreciation and future capacity.
Impact: PPE, depreciation, and cash flow
Changes in definition and restatements affect trend analysis and peer comparability.
Impact: Cash flow presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
NewAmsterdam Pharma Co N.V.
NAMS · Pharmaceutical Preparations
Nu-Med Plus, Inc.
NUMD · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care, Inc
TNDM · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy.
Novartis AG
NVS · Pharmaceutical Preparations
Novartis AG is a Switzerland-based medicines company that discovers, develops, manufactures, and commercializes prescription therapies across a broad range of therapeutic areas.
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
Insulet Corporation
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
Last updated: 24/10/2026